U.S. Approves AstraZeneca’s Breztri Aerosphere to Treat COPD

AstraZeneca to make a $150 million milestone payment on FDA’s approval of Breztri Aerosphere for maintenance treatment of patients with chronic obstructive pulmonary disease, according to statement.

• Milestone payment part of agreement to buy Pearl Therapeutics
• FDA approval based on positive results from Phase III ETHOS trial
• NOTE, June 24: AstraZeneca: Phase 3 ETHOS Trial Results Meet Secondary Endpoint

To contact the reporter on this story:
Alexander Pearson in Frankfurt at apearson50@bloomberg.net

To contact the editors responsible for this story:
Wout Vergauwen at wvergauwen@bloomberg.net

Leonard Kehnscherper

© 2020 Bloomberg L.P. All rights reserved. Used with permission.